Effect of chronic morphine on the dentate gyrus neurogenic microenvironment.
Opiates, such as morphine, decrease neurogenesis in the postnatal hippocampal subgranular zone (SGZ) by inhibiting progenitor proliferation and maturation. However, it is not known how morphine influences the growth factors and vasculature that encompass the neurogenic SGZ microenvironment. We examined morphine's effect on pro- and anti-proliferative factors in the dentate gyrus (DG; Experiment 1) as well as the DG neurovasculature itself (Experiment 2). For Experiment 1, mice were implanted with subcutaneous sham or morphine pellets (0 and 48 h) and were decapitated 24 or 96 h later. One brain hemisphere was postfixed to examine proliferation by immunohistochemistry, and a DG-enriched sample was dissected from the other hemisphere to examine the neurogenic microenvironment via immunoblotting for known pro- and anti-proliferative factors. Consistent with previous results, morphine decreased the number of proliferating cells in the SGZ, as the number of Ki67-immunoreactive (IR) cells was decreased at 96 h. Morphine did not alter DG levels of the pro-proliferative factor brain-derived neurotrophic factor, anti-proliferative factor interleukin-1 beta, or their receptors TrkB and IL1R1 at either time point. However, morphine increased the pro-proliferative factor vascular endothelial growth factor (VEGF) at 96 h. Given that VEGF is also a potent angiogenic factor, Experiment 2 examined whether the morphine-induced increase in VEGF correlated with altered DG neurovasculature. Mice were implanted with morphine pellets as in Experiment 1, and 2 h before perfusion (24 or 96 h) were administered bromodeoxyuridine (BrdU; intraperitoneal, 150 mg/kg). Tissue was co-stained for BrdU and the endothelial cell marker endoglin to enable examination of DG vessels and proximity of BrdU-IR cells to endoglin-IR vessels. At 96 h, endoglin-IR vessel area and perimeter were increased, but proximity of BrdU-IR cells to endoglin-IR vessels remained unchanged. These data suggest that following chronic morphine exposure, factors within the neurogenic microenvironment are maintained or upregulated to compensate for decreased SGZ proliferation.
Arguello
A A
AA
Department of Psychiatry, University of Texas Southwestern Medical Center at Dallas, Dallas, TX 75390-9070, USA.
Fischer
S J
SJ
Schonborn
J R
JR
Markus
R W
RW
Brekken
R A
RA
Eisch
A J
AJ
D000701:Analgesics, Opioid / Q000633:toxicity*; D000818:Animals; D019208:Brain-Derived Neurotrophic Factor / Q000378:metabolism; D018891:Dentate Gyrus / Q000098:blood supply* / Q000187:drug effects* / Q000502:physiology; D000071063:Endoglin; D006624:Hippocampus / Q000098:blood supply / Q000187:drug effects / Q000502:physiology; D015151:Immunoblotting; D007150:Immunohistochemistry; D053583:Interleukin-1beta / Q000378:metabolism; D047908:Intracellular Signaling Peptides and Proteins / Q000378:metabolism; D019394:Ki-67 Antigen / Q000378:metabolism; D051379:Mice; D008810:Mice, Inbred C57BL; D009020:Morphine / Q000633:toxicity*; D055495:Neurogenesis / Q000187:drug effects* / Q000502:physiology; D009474:Neurons / Q000187:drug effects / Q000502:physiology; D020813:Receptor, trkB / Q000378:metabolism; D053573:Receptors, Interleukin-1 Type I / Q000378:metabolism; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism
D000701:Analgesics, Opioid; D019208:Brain-Derived Neurotrophic Factor; D000071063:Endoglin; C502004:Eng protein, mouse; D053583:Interleukin-1beta; D047908:Intracellular Signaling Peptides and Proteins; D019394:Ki-67 Antigen; D053573:Receptors, Interleukin-1 Type I; D042461:Vascular Endothelial Growth Factor A; D009020:Morphine; D020813:Receptor, trkB